New occurrence records extend the northern distribution of Dromiciops in Argentina

En esta nota reportamos cinco nuevas localidades para el género Dromiciops, a partir de registros con trampas cámara y el hallazgo de un individuo muerto, todos provenientes de bosques de Nothofagus en la provincia del Neuquén (República Argentina). Estos nuevos registros expanden la distribución conocida del género casi 300 kilómetros al norte en su distribución en Argentina. Estas localidades corresponderían, posiblemente, a la especie D. bozinovici.In this note we report five new localities for the genus Dromiciops, based on camera trap records and the finding of a dead individual, all from Nothofagus forests in the province of Neuquén (Argentina). These new records expand the known distribution of the genus almost 300 km to the north. These localities probably correspond to the species D. bozinovici.Fil: Vazquez, Miriam Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte. Instituto de Investigaciones en Biodiversidad y Medioambiente. Universidad Nacional del Comahue. Centro Regional Universidad Bariloche. Instituto de Investigaciones en Biodiversidad y Medioambiente; ArgentinaFil: Viviani, Debora. Gobierno de la Provincia de Neuquén. Dirección Provincial de Áreas Naturales Protegidas y Recursos Faunísticos; ArgentinaFil: Mora, Wenceslao. Gobierno de la Provincia de Neuquén. Dirección Provincial de Áreas Naturales Protegidas y Recursos Faunísticos; ArgentinaFil: Aubone, Mariana. Gobierno de la Provincia de Neuquén. Dirección Provincial de Áreas Naturales Protegidas y Recursos Faunísticos; ArgentinaFil: Amico, Guillermo Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte. Instituto de Investigaciones en Biodiversidad y Medioambiente. Universidad Nacional del Comahue. Centro Regional Universidad Bariloche. Instituto de Investigaciones en Biodiversidad y Medioambiente; Argentin

Application of a novel respirometric methodology to characterize mass transfer and activity of H2S-oxidizing biofilms in biotrickling filter beds

The elimination capacity of gaseous H2S biofiltration can be limited either by mass transfer or bioreaction in the biofilm. Assessment of the biological activity of immobilized cells (biofilm) usually implies morphological and physiological changes during the adaptation of cells to respirometric devices operated as suspended cultures. In this study, respirometry of heterogeneous media is advised as a valuable technique for characterizing mass transport and biological activity of H2S-oxidizing biofilms attached on two packing materials from operative biotrickling filters. Controlled flows of liquid and H2S-containing air were recirculated through a closed heterogeneous respirometer allowing a more realistic estimation of the biofilm activity by the experimental evaluation of the oxygen uptake rate (OUR). Specific maximum OUR of 23.0 and 38.5 mmol O-2 (g biomass min)(-1) were obtained for Pall rings and polyurethane foam, respectively. A mathematical model for the determination of kinetic-related parameters such as the maximum H2S elimination capacity and morphological properties of biofilm (i.e., thickness and fraction of wetted area of packing bed) was developed and calibrated. With the set of parameters obtained, the external oxygen mass transport to the wetted biofilm was found to limit the global H2S biofiltration capacity, whereas the non-wetted biofilm was the dominant route for the gaseous O-2 and H2S mass transfer to the biofilm. Oxygen diffusion rate was the limiting step in the case of very active biofilms.Peer ReviewedPostprint (author’s final draft

A prognostic DNA methylation signature for stage I non-small-cell lung cancer

Purpose Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high-and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging. (C) 2013 by American Society of Clinical Oncology

Application of a novel respirometric methodology to characterize mass transfer and activity of H2S-oxidizing biofilms in biotrickling filter beds

The elimination capacity of gaseous H2S biofiltration can be limited either by mass transfer or bioreaction in the biofilm. Assessment of the biological activity of immobilized cells (biofilm) usually implies morphological and physiological changes during the adaptation of cells to respirometric devices operated as suspended cultures. In this study, respirometry of heterogeneous media is advised as a valuable technique for characterizing mass transport and biological activity of H2S-oxidizing biofilms attached on two packing materials from operative biotrickling filters. Controlled flows of liquid and H2S-containing air were recirculated through a closed heterogeneous respirometer allowing a more realistic estimation of the biofilm activity by the experimental evaluation of the oxygen uptake rate (OUR). Specific maximum OUR of 23.0 and 38.5 mmol O-2 (g biomass min)(-1) were obtained for Pall rings and polyurethane foam, respectively. A mathematical model for the determination of kinetic-related parameters such as the maximum H2S elimination capacity and morphological properties of biofilm (i.e., thickness and fraction of wetted area of packing bed) was developed and calibrated. With the set of parameters obtained, the external oxygen mass transport to the wetted biofilm was found to limit the global H2S biofiltration capacity, whereas the non-wetted biofilm was the dominant route for the gaseous O-2 and H2S mass transfer to the biofilm. Oxygen diffusion rate was the limiting step in the case of very active biofilms.Peer Reviewe

A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer

PURPOSE: Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard.PATIENTS AND METHODS: A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC.RESULTS: Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high- and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001).CONCLUSION: The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging.</p

Impact of the International Nosocomial Infection Control Consortium's multidimensional approach on rates of ventilator-associated pneumonia in 14 intensive care units in 11 hospitals of 5 cities within Argentina

Background: To analyze the impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach (IMA) on ventilator-associated pneumonia (VAP) rates in 11 hospitals within 5 cities of Argentina from January 2014-April 2017. Methods: A multicenter, prospective, before–after surveillance study was conducted through the use of International Nosocomial Infection Control Consortium Surveillance Online System. During baseline, we performed outcome surveillance of VAP applying the definitions of the Centers for Disease Control andPrevention's National Healthcare Safety Network. During intervention, we implemented the IMA, which included a bundle of infection prevention practice interventions, education, outcome surveillance, process surveillance, feedback on VAP rates and consequences, and performance feedback of process surveillance. Bivariate and multivariate regression analyses were performed using a logistic regression model to estimate the effect of the intervention. Results: We recorded 3,940 patients admitted to 14 intensive care units. At baseline, there were 19.9 VAPs per 1,000 mechanical ventilator (MV)-days—with 2,920 MV-days and 58 VAPs, which was reduced during intervention to 9.4 VAPs per 1,000 MV-days—with 9,261 MV-days and 103 VAPs. This accounted for a 52% rate reduction (incidence density rate, 0.48; 95% confidence interval, 0.3-0.7; P.001). Conclusions: Implementing the IMA was associated with significant reductions in VAP rates in intensive care units within Argentina.Fil: Rosenthal, Victor Daniel. International Nosocomial Infection Control Consortium; ArgentinaFil: Desse, Javier. Sanatorio San Cayetano; ArgentinaFil: Maurizi, Diego Marcelo. Hospital Privado del Sur; Argentina. Hospital Municipal Doctor Leónidas Lucero; ArgentinaFil: Chaparro, Gustavo Jorge. No especifíca;Fil: Orellano, Pablo Wenceslao. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Tecnológica Nacional. Facultad Regional San Nicolás; ArgentinaFil: Chediack, Viviana. Policlínico Central Unión Obrera Metalúrgica; ArgentinaFil: Cabrera, Rafael. No especifíca;Fil: Golschmid, Daniel. Hospital Privado Raul Matera; ArgentinaFil: Silva, Cristina Graciela. No especifíca;Fil: Vimercati, Julio Cesar. No especifíca;Fil: Stagnaro, Juan Pablo. Instituto Central de Medicina; ArgentinaFil: Perez, Ivanna. Clínica San Cayetano; ArgentinaFil: Spadaro, María Laura. Hospital Privado Raul Matera; ArgentinaFil: Montanini, Adriana Miriam. Hospital Municipal Doctor Leónidas Lucero; ArgentinaFil: Pedersen, Dina. Hospital Municipal Doctor Leónidas Lucero; ArgentinaFil: Paniccia, Teresa Laura. Hospital Municipal Doctor Leónidas Lucero; ArgentinaFil: Ríos Aguilera, Ana María. Hospital Privado del Sur; ArgentinaFil: Cermesoni, Raul. Hospital Privado del Sur; ArgentinaFil: Mele, Juan Ignacio. Hospital Privado del Sur; ArgentinaFil: Alda, Ernesto. Hospital Privado del Sur; ArgentinaFil: Paldoro, Analía Edith. No especifíca;Fil: Ortta, Agustín Román. No especifíca;Fil: Cooke, Bettina. No especifíca;Fil: García, María Cecilia. No especifíca;Fil: Obed, Mora Nair. No especifíca;Fil: Domínguez, Cecilia Verónica. Policlínico Central Unión Obrera Metalúrgica; ArgentinaFil: Saúl, Pablo Alejandro. Policlínico Central Unión Obrera Metalúrgica; ArgentinaFil: Rodríguez del Valle, María Cecilia. Hospital Zonal General de Agudos Dr Ricardo Gutiérrez; ArgentinaFil: Bianchi, Alberto Claudio. Hospital Zonal General de Agudos Dr Ricardo Gutiérrez; ArgentinaFil: Alvarez, Gustavo. Instituto Central de Medicina; ArgentinaFil: Pérez, Ricardo. Instituto Central de Medicina; ArgentinaFil: Oyola, Carolina. No especifíca

Impact of the International Nosocomial Infection Control Consortium (INICC)'s Multidimensional Approach on Rates of Central Line-Associated Bloodstream Infection in 14 Intensive Care Units in 11 Hospitals of 5 Cities in Argentina

OBJECTIVE To analyze the impact of the International Nosocomial Infection Control Consortium (INICC) Multidimensional Approach (IMA) and the INICC Surveillance Online System (ISOS) on central line-associated bloodstream infection (CLABSI) rates in 14 intensive care units (ICUs) in Argentina from January 2014 to April 2017. DESIGN This prospective, pre-post surveillance study of 3,940 ICU patients was conducted in 11 hospitals in 5 cities in Argentina. During our baseline evaluation, we performed outcome and process surveillance of CLABSI applying Centers for Disease Control and Prevention/National Health Safety Network (CDC/NHSN) definitions. During the intervention, we implemented the IMA through ISOS: (1) a bundle of infection prevention practice interventions, (2) education, (3) outcome surveillance, (4) process surveillance, (5) feedback on CLABSI rates and consequences, and (6) performance feedback of process surveillance. Bivariate and multivariate regression analyses were performed using a logistic regression model to estimate the effect of the intervention on the CLABSI rate. RESULTS During the baseline period, 5,118 CL days and 49 CLABSIs were recorded, for a rate of 9.6 CLABSIs per 1,000 central-line (CL) days. During the intervention, 15,659 CL days and 68 CLABSIs were recorded, for a rate of 4.1 CLABSIs per 1,000 CL days. The CLABSI rate was reduced by 57% (incidence density rate: 0.43; 95% confidence interval, 0.34-0.6; P<.001). CONCLUSIONS Implementing IMA through ISOS was associated with a significant reduction in the CLABSI rate in ICUs in Argentina. Infect Control Hosp Epidemiol 2018;39:445-45

A prognostic DNA methylation signature for stage I non-small-cell lung cancer

Purpose Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high-and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging. (C) 2013 by American Society of Clinical Oncology